AG˹ٷ

STOCK TITAN

[Form 4] ZYNEX INC Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Zynex Inc. (ZYXI) � Form 4 filing, 29 Jul 2025. Chief Operating Officer Anna Lucsok reported two equity-compensation transactions.

  • Restricted Stock Award: On 27 Jul 2025 Lucsok received 7,500 common shares under the 2017 Stock Incentive Plan. The grant vests in equal annual tranches over four years and was issued at $0 cost.
  • Tax-Withholding Share Surrender: On 28 Jul 2025 the issuer withheld 3,793 shares (Code F) at an implied value of $2.56 per share to cover payroll taxes related to previously vested RSAs. This is not an open-market sale.

After the transactions, Lucsok directly holds 64,412 shares, most of which remain unvested. No derivatives were involved and there were no cash sales or purchases. The filing modestly increases insider ownership alignment but has immaterial dilution given Zynex’s overall share count. Investor impact is therefore limited and chiefly informative for governance monitoring.

Zynex Inc. (ZYXI) � Comunicazione Form 4, 29 luglio 2025. La Chief Operating Officer Anna Lucsok ha segnalato due operazioni di compensazione azionaria.

  • Assegnazione di Azioni Vincolate: Il 27 luglio 2025 Lucsok ha ricevuto 7.500 azioni ordinarie nell’ambito del Piano Incentivi Azionari 2017. L’assegnazione si consolida in quote annuali uguali per quattro anni ed è stata emessa senza alcun costo.
  • Consegna di Azioni per Ritenuta Fiscale: Il 28 luglio 2025 l’emittente ha trattenuto 3.793 azioni (Codice F) al valore implicito di 2,56 $ per azione per coprire le imposte sul reddito relative a precedenti azioni vincolate già maturate. Non si tratta di una vendita sul mercato aperto.

Dopo queste operazioni, Lucsok detiene direttamente 64.412 azioni, la maggior parte delle quali non ancora consolidate. Non sono stati coinvolti strumenti derivati né ci sono state vendite o acquisti in contanti. La comunicazione aumenta leggermente l’allineamento della proprietà interna ma comporta una diluzione irrilevante considerando il numero complessivo di azioni di Zynex. L’impatto per gli investitori è quindi limitato e principalmente informativo per il monitoraggio della governance.

Zynex Inc. (ZYXI) � Presentación Formulario 4, 29 de julio de 2025. La Directora de Operaciones Anna Lucsok reportó dos transacciones de compensación en acciones.

  • Asignación de Acciones Restringidas: El 27 de julio de 2025 Lucsok recibió 7,500 acciones ordinarias bajo el Plan de Incentivos de Acciones 2017. La concesión se consolida en partes iguales anualmente durante cuatro años y fue otorgada sin costo.
  • Entrega de Acciones para Retención Fiscal: El 28 de julio de 2025 el emisor retuvo 3,793 acciones (Código F) a un valor implícito de $2.56 por acción para cubrir impuestos sobre la nómina relacionados con RSAs previamente consolidadas. Esto no es una venta en el mercado abierto.

Tras las transacciones, Lucsok posee directamente 64,412 acciones, la mayoría aún no consolidadas. No se involucraron derivados ni hubo ventas o compras en efectivo. La presentación incrementa modestamente la alineación de propiedad interna pero genera una dilución insignificante considerando el total de acciones de Zynex. Por lo tanto, el impacto para inversores es limitado y principalmente informativo para el seguimiento de la gobernanza.

Zynex Inc. (ZYXI) � 2025� 7� 29� Form 4 제출. 최고운영책임�(Chief Operating Officer) 안나 럭속(Anna Lucsok)� � 건의 주식 보상 거래� 보고했습니다.

  • 제한 주식 수여: 2025� 7� 27�, 럭속은 2017� 주식 인센티브 플랜� 따라 7,500 보통주를 받았습니�. 해당 보조금은 4년에 걸쳐 매년 동일� 비율� 취득되며, 비용 없이 발행되었습니�.
  • 세금 원천징수 주식 반환: 2025� 7� 28�, 발행사는 이전� 취득� 제한 주식(RSA)� 대� 급여세를 충당하기 위해 암시� 주당 2.56달러 가치로 3,793�(Code F)� 원천징수했습니다. 이는 공개 시장 판매가 아닙니다.

거래 � 럭속은 직접 64,412주를 보유하며, 대부분은 아직 취득되지 않은 상태입니�. 파생상품은 없었� 현금 매매� 없었습니�. 이번 제출은 내부� 소유� 정렬� 소폭 높였으나 Zynex� 전체 주식 수를 고려� � 미미� 희석 효과� 가집니�. 따라� 투자� 영향은 제한적이� 주로 거버넌스 모니터링� 위한 정보 제공 목적입니�.

Zynex Inc. (ZYXI) � Dépôt Formulaire 4, 29 juillet 2025. La Directrice des Opérations Anna Lucsok a déclaré deux opérations de rémunération en actions.

  • Attribution d’Actions Restreintes : Le 27 juillet 2025, Lucsok a reçu 7 500 actions ordinaires dans le cadre du Plan d’Incitation en Actions 2017. L’attribution se libère par tranches annuelles égales sur quatre ans et a été accordée sans coût.
  • Remise d’Actions pour Retenue Fiscale : Le 28 juillet 2025, l’émetteur a retenu 3 793 actions (Code F) à une valeur implicite de 2,56 $ par action pour couvrir les impôts sur la paie liés aux RSAs déjà acquises. Il ne s’agit pas d’une vente sur le marché libre.

Après ces opérations, Lucsok détient directement 64 412 actions, dont la plupart ne sont pas encore acquises. Aucun dérivé n’a été impliqué et il n’y a eu ni vente ni achat en espèces. Le dépôt augmente modestement l’alignement de la propriété interne mais entraîne une dilution négligeable compte tenu du nombre total d’actions de Zynex. L’impact pour les investisseurs est donc limité et principalement informatif pour le suivi de la gouvernance.

Zynex Inc. (ZYXI) � Form 4 Einreichung, 29. Juli 2025. Die Chief Operating Officer Anna Lucsok meldete zwei Transaktionen im Rahmen der Aktienvergütung.

  • Restricted Stock Award: Am 27. Juli 2025 erhielt Lucsok 7.500 Stammaktien gemäß dem Aktienanreizplan 2017. Die Zuteilung wird gleichmäßig über vier Jahre jährlich vestet und wurde ohne Kosten ausgegeben.
  • Steuerabzugs-Aktienabgabe: Am 28. Juli 2025 behielt der Emittent 3.793 Aktien (Code F) zum impliziten Wert von 2,56 $ pro Aktie ein, um die Lohnsteuern für zuvor vestete RSAs zu begleichen. Dies ist kein Verkauf am offenen Markt.

Nach den Transaktionen hält Lucsok direkt 64.412 Aktien, von denen die meisten noch nicht vestet sind. Es wurden keine Derivate verwendet und keine Barverkäufe oder -käufe getätigt. Die Einreichung erhöht die innere Eigentümerbindung leicht, verursacht aber angesichts der Gesamtzahl der Zynex-Aktien eine unwesentliche Verwässerung. Die Auswirkung für Investoren ist daher begrenzt und hauptsächlich informativ für die Überwachung der Unternehmensführung.

Positive
  • No open-market sale; shares withheld solely for taxes, avoiding negative signal.
  • Additional 7,500-share grant increases executive’s long-term equity stake, aligning incentives.
Negative
  • Minor dilution from new shares, though likely immaterial to float.
  • Four-year vesting delays full alignment and could still result in future sales upon vesting.

Insights

TL;DR: Routine equity grant; no open-market selling, negligible dilution; neutral governance signal.

The COO’s 7,500-share RSA aligns compensation with long-term performance while 3,793 shares were automatically withheld for taxes—standard Plan mechanics. Net insider exposure rises slightly, totaling 64,412 shares. Because no sale occurred and the quantity is immaterial to float, market impact should be neutral; nonetheless, continued insider accumulation is a modestly positive alignment factor.

TL;DR: Insider keeps skin in the game; too small to affect valuation.

From a portfolio viewpoint this filing does not change the ZYXI thesis. Grants are typical for C-suite retention and the withholding transaction is tax-driven. With no open-market activity and fewer than 0.2% of shares affected (estimate), liquidity and sentiment remain unchanged. I assign a neutral trading signal.

Zynex Inc. (ZYXI) � Comunicazione Form 4, 29 luglio 2025. La Chief Operating Officer Anna Lucsok ha segnalato due operazioni di compensazione azionaria.

  • Assegnazione di Azioni Vincolate: Il 27 luglio 2025 Lucsok ha ricevuto 7.500 azioni ordinarie nell’ambito del Piano Incentivi Azionari 2017. L’assegnazione si consolida in quote annuali uguali per quattro anni ed è stata emessa senza alcun costo.
  • Consegna di Azioni per Ritenuta Fiscale: Il 28 luglio 2025 l’emittente ha trattenuto 3.793 azioni (Codice F) al valore implicito di 2,56 $ per azione per coprire le imposte sul reddito relative a precedenti azioni vincolate già maturate. Non si tratta di una vendita sul mercato aperto.

Dopo queste operazioni, Lucsok detiene direttamente 64.412 azioni, la maggior parte delle quali non ancora consolidate. Non sono stati coinvolti strumenti derivati né ci sono state vendite o acquisti in contanti. La comunicazione aumenta leggermente l’allineamento della proprietà interna ma comporta una diluzione irrilevante considerando il numero complessivo di azioni di Zynex. L’impatto per gli investitori è quindi limitato e principalmente informativo per il monitoraggio della governance.

Zynex Inc. (ZYXI) � Presentación Formulario 4, 29 de julio de 2025. La Directora de Operaciones Anna Lucsok reportó dos transacciones de compensación en acciones.

  • Asignación de Acciones Restringidas: El 27 de julio de 2025 Lucsok recibió 7,500 acciones ordinarias bajo el Plan de Incentivos de Acciones 2017. La concesión se consolida en partes iguales anualmente durante cuatro años y fue otorgada sin costo.
  • Entrega de Acciones para Retención Fiscal: El 28 de julio de 2025 el emisor retuvo 3,793 acciones (Código F) a un valor implícito de $2.56 por acción para cubrir impuestos sobre la nómina relacionados con RSAs previamente consolidadas. Esto no es una venta en el mercado abierto.

Tras las transacciones, Lucsok posee directamente 64,412 acciones, la mayoría aún no consolidadas. No se involucraron derivados ni hubo ventas o compras en efectivo. La presentación incrementa modestamente la alineación de propiedad interna pero genera una dilución insignificante considerando el total de acciones de Zynex. Por lo tanto, el impacto para inversores es limitado y principalmente informativo para el seguimiento de la gobernanza.

Zynex Inc. (ZYXI) � 2025� 7� 29� Form 4 제출. 최고운영책임�(Chief Operating Officer) 안나 럭속(Anna Lucsok)� � 건의 주식 보상 거래� 보고했습니다.

  • 제한 주식 수여: 2025� 7� 27�, 럭속은 2017� 주식 인센티브 플랜� 따라 7,500 보통주를 받았습니�. 해당 보조금은 4년에 걸쳐 매년 동일� 비율� 취득되며, 비용 없이 발행되었습니�.
  • 세금 원천징수 주식 반환: 2025� 7� 28�, 발행사는 이전� 취득� 제한 주식(RSA)� 대� 급여세를 충당하기 위해 암시� 주당 2.56달러 가치로 3,793�(Code F)� 원천징수했습니다. 이는 공개 시장 판매가 아닙니다.

거래 � 럭속은 직접 64,412주를 보유하며, 대부분은 아직 취득되지 않은 상태입니�. 파생상품은 없었� 현금 매매� 없었습니�. 이번 제출은 내부� 소유� 정렬� 소폭 높였으나 Zynex� 전체 주식 수를 고려� � 미미� 희석 효과� 가집니�. 따라� 투자� 영향은 제한적이� 주로 거버넌스 모니터링� 위한 정보 제공 목적입니�.

Zynex Inc. (ZYXI) � Dépôt Formulaire 4, 29 juillet 2025. La Directrice des Opérations Anna Lucsok a déclaré deux opérations de rémunération en actions.

  • Attribution d’Actions Restreintes : Le 27 juillet 2025, Lucsok a reçu 7 500 actions ordinaires dans le cadre du Plan d’Incitation en Actions 2017. L’attribution se libère par tranches annuelles égales sur quatre ans et a été accordée sans coût.
  • Remise d’Actions pour Retenue Fiscale : Le 28 juillet 2025, l’émetteur a retenu 3 793 actions (Code F) à une valeur implicite de 2,56 $ par action pour couvrir les impôts sur la paie liés aux RSAs déjà acquises. Il ne s’agit pas d’une vente sur le marché libre.

Après ces opérations, Lucsok détient directement 64 412 actions, dont la plupart ne sont pas encore acquises. Aucun dérivé n’a été impliqué et il n’y a eu ni vente ni achat en espèces. Le dépôt augmente modestement l’alignement de la propriété interne mais entraîne une dilution négligeable compte tenu du nombre total d’actions de Zynex. L’impact pour les investisseurs est donc limité et principalement informatif pour le suivi de la gouvernance.

Zynex Inc. (ZYXI) � Form 4 Einreichung, 29. Juli 2025. Die Chief Operating Officer Anna Lucsok meldete zwei Transaktionen im Rahmen der Aktienvergütung.

  • Restricted Stock Award: Am 27. Juli 2025 erhielt Lucsok 7.500 Stammaktien gemäß dem Aktienanreizplan 2017. Die Zuteilung wird gleichmäßig über vier Jahre jährlich vestet und wurde ohne Kosten ausgegeben.
  • Steuerabzugs-Aktienabgabe: Am 28. Juli 2025 behielt der Emittent 3.793 Aktien (Code F) zum impliziten Wert von 2,56 $ pro Aktie ein, um die Lohnsteuern für zuvor vestete RSAs zu begleichen. Dies ist kein Verkauf am offenen Markt.

Nach den Transaktionen hält Lucsok direkt 64.412 Aktien, von denen die meisten noch nicht vestet sind. Es wurden keine Derivate verwendet und keine Barverkäufe oder -käufe getätigt. Die Einreichung erhöht die innere Eigentümerbindung leicht, verursacht aber angesichts der Gesamtzahl der Zynex-Aktien eine unwesentliche Verwässerung. Die Auswirkung für Investoren ist daher begrenzt und hauptsächlich informativ für die Überwachung der Unternehmensführung.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Lucsok Anna

(Last) (First) (Middle)
9655 MAROON CIRCLE

(Street)
ENGLEWOOD CO 80112

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ZYNEX INC [ ZYXI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF OPERATING OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
07/27/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock (Restricted Stock Award) 07/27/2025 A 7,500(1) A $0 64,412(2) D
Common Stock 07/28/2025 F 3,793(3) D $2.56 40,856 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents a restricted stock award issued pursuant to the Issuer's 2017 Stock Incentive Plan (the "Plan") pursuant to which the 7,500 shares vest equally, on an annual basis, over a period of four years beginning one year from the grant date.
2. Represents restricted stock awards under the Plan, which have not vested.
3. Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of Restricted Stock Awards ("RSAs") and does not represent a sale.
/s/ Anna Lucsok 07/29/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many ZYXI shares did COO Anna Lucsok acquire?

She received 7,500 restricted shares on 27 Jul 2025.

Were any ZYXI shares sold in the market?

No. 3,793 shares were withheld by the company for tax purposes; no market sale occurred.

What is the executive’s total direct ownership after the filing?

Lucsok now directly holds 64,412 ZYXI shares.

When will the new restricted shares vest?

They vest in four equal annual tranches starting one year from the grant date.

Does the filing involve any derivative securities?

No derivative securities were reported in Table II.
Zynex Inc

NASDAQ:ZYXI

ZYXI Rankings

ZYXI Latest News

ZYXI Latest SEC Filings

ZYXI Stock Data

75.29M
15.61M
45.64%
26.67%
13.86%
Medical Distribution
Electromedical & Electrotherapeutic Apparatus
United States
ENGLEWOOD